Immune Dysregulation and the Increased Risk of Complications and Mortality Following Respiratory Tract Infections in Adults With Down Syndrome
The risk of severe outcomes following respiratory tract infections is significantly increased in individuals over 60 years, especially in those with chronic medical conditions, i.e., hypertension, diabetes, cardiovascular disease, dementia, chronic respiratory disease, and cancer. Down Syndrome (DS)...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.621440/full |
| id |
doaj-cdbe71e884d1479b9d8fdfcd805105d1 |
|---|---|
| record_format |
Article |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Tomer Illouz Tomer Illouz Arya Biragyn Maria Florencia Iulita Maria Florencia Iulita Maria Florencia Iulita Lisi Flores-Aguilar Mara Dierssen Mara Dierssen Mara Dierssen Ilario De Toma Ilario De Toma Ilario De Toma Stylianos E. Antonarakis Stylianos E. Antonarakis Stylianos E. Antonarakis Eugene Yu Eugene Yu Yann Herault Marie-Claude Potier Alexandra Botté Randall Roper Benjamin Sredni Jacqueline London William Mobley Andre Strydom Andre Strydom Eitan Okun Eitan Okun Eitan Okun |
| spellingShingle |
Tomer Illouz Tomer Illouz Arya Biragyn Maria Florencia Iulita Maria Florencia Iulita Maria Florencia Iulita Lisi Flores-Aguilar Mara Dierssen Mara Dierssen Mara Dierssen Ilario De Toma Ilario De Toma Ilario De Toma Stylianos E. Antonarakis Stylianos E. Antonarakis Stylianos E. Antonarakis Eugene Yu Eugene Yu Yann Herault Marie-Claude Potier Alexandra Botté Randall Roper Benjamin Sredni Jacqueline London William Mobley Andre Strydom Andre Strydom Eitan Okun Eitan Okun Eitan Okun Immune Dysregulation and the Increased Risk of Complications and Mortality Following Respiratory Tract Infections in Adults With Down Syndrome Frontiers in Immunology Down syndrome immune dysregulation hospitalization respiratory tract infections interferon COVID-19 |
| author_facet |
Tomer Illouz Tomer Illouz Arya Biragyn Maria Florencia Iulita Maria Florencia Iulita Maria Florencia Iulita Lisi Flores-Aguilar Mara Dierssen Mara Dierssen Mara Dierssen Ilario De Toma Ilario De Toma Ilario De Toma Stylianos E. Antonarakis Stylianos E. Antonarakis Stylianos E. Antonarakis Eugene Yu Eugene Yu Yann Herault Marie-Claude Potier Alexandra Botté Randall Roper Benjamin Sredni Jacqueline London William Mobley Andre Strydom Andre Strydom Eitan Okun Eitan Okun Eitan Okun |
| author_sort |
Tomer Illouz |
| title |
Immune Dysregulation and the Increased Risk of Complications and Mortality Following Respiratory Tract Infections in Adults With Down Syndrome |
| title_short |
Immune Dysregulation and the Increased Risk of Complications and Mortality Following Respiratory Tract Infections in Adults With Down Syndrome |
| title_full |
Immune Dysregulation and the Increased Risk of Complications and Mortality Following Respiratory Tract Infections in Adults With Down Syndrome |
| title_fullStr |
Immune Dysregulation and the Increased Risk of Complications and Mortality Following Respiratory Tract Infections in Adults With Down Syndrome |
| title_full_unstemmed |
Immune Dysregulation and the Increased Risk of Complications and Mortality Following Respiratory Tract Infections in Adults With Down Syndrome |
| title_sort |
immune dysregulation and the increased risk of complications and mortality following respiratory tract infections in adults with down syndrome |
| publisher |
Frontiers Media S.A. |
| series |
Frontiers in Immunology |
| issn |
1664-3224 |
| publishDate |
2021-06-01 |
| description |
The risk of severe outcomes following respiratory tract infections is significantly increased in individuals over 60 years, especially in those with chronic medical conditions, i.e., hypertension, diabetes, cardiovascular disease, dementia, chronic respiratory disease, and cancer. Down Syndrome (DS), the most prevalent intellectual disability, is caused by trisomy-21 in ~1:750 live births worldwide. Over the past few decades, a substantial body of evidence has accumulated, pointing at the occurrence of alterations, impairments, and subsequently dysfunction of the various components of the immune system in individuals with DS. This associates with increased vulnerability to respiratory tract infections in this population, such as the influenza virus, respiratory syncytial virus, SARS-CoV-2 (COVID-19), and bacterial pneumonias. To emphasize this link, here we comprehensively review the immunobiology of DS and its contribution to higher susceptibility to severe illness and mortality from respiratory tract infections. |
| topic |
Down syndrome immune dysregulation hospitalization respiratory tract infections interferon COVID-19 |
| url |
https://www.frontiersin.org/articles/10.3389/fimmu.2021.621440/full |
| work_keys_str_mv |
AT tomerillouz immunedysregulationandtheincreasedriskofcomplicationsandmortalityfollowingrespiratorytractinfectionsinadultswithdownsyndrome AT tomerillouz immunedysregulationandtheincreasedriskofcomplicationsandmortalityfollowingrespiratorytractinfectionsinadultswithdownsyndrome AT aryabiragyn immunedysregulationandtheincreasedriskofcomplicationsandmortalityfollowingrespiratorytractinfectionsinadultswithdownsyndrome AT mariaflorenciaiulita immunedysregulationandtheincreasedriskofcomplicationsandmortalityfollowingrespiratorytractinfectionsinadultswithdownsyndrome AT mariaflorenciaiulita immunedysregulationandtheincreasedriskofcomplicationsandmortalityfollowingrespiratorytractinfectionsinadultswithdownsyndrome AT mariaflorenciaiulita immunedysregulationandtheincreasedriskofcomplicationsandmortalityfollowingrespiratorytractinfectionsinadultswithdownsyndrome AT lisifloresaguilar immunedysregulationandtheincreasedriskofcomplicationsandmortalityfollowingrespiratorytractinfectionsinadultswithdownsyndrome AT maradierssen immunedysregulationandtheincreasedriskofcomplicationsandmortalityfollowingrespiratorytractinfectionsinadultswithdownsyndrome AT maradierssen immunedysregulationandtheincreasedriskofcomplicationsandmortalityfollowingrespiratorytractinfectionsinadultswithdownsyndrome AT maradierssen immunedysregulationandtheincreasedriskofcomplicationsandmortalityfollowingrespiratorytractinfectionsinadultswithdownsyndrome AT ilariodetoma immunedysregulationandtheincreasedriskofcomplicationsandmortalityfollowingrespiratorytractinfectionsinadultswithdownsyndrome AT ilariodetoma immunedysregulationandtheincreasedriskofcomplicationsandmortalityfollowingrespiratorytractinfectionsinadultswithdownsyndrome AT ilariodetoma immunedysregulationandtheincreasedriskofcomplicationsandmortalityfollowingrespiratorytractinfectionsinadultswithdownsyndrome AT stylianoseantonarakis immunedysregulationandtheincreasedriskofcomplicationsandmortalityfollowingrespiratorytractinfectionsinadultswithdownsyndrome AT stylianoseantonarakis immunedysregulationandtheincreasedriskofcomplicationsandmortalityfollowingrespiratorytractinfectionsinadultswithdownsyndrome AT stylianoseantonarakis immunedysregulationandtheincreasedriskofcomplicationsandmortalityfollowingrespiratorytractinfectionsinadultswithdownsyndrome AT eugeneyu immunedysregulationandtheincreasedriskofcomplicationsandmortalityfollowingrespiratorytractinfectionsinadultswithdownsyndrome AT eugeneyu immunedysregulationandtheincreasedriskofcomplicationsandmortalityfollowingrespiratorytractinfectionsinadultswithdownsyndrome AT yannherault immunedysregulationandtheincreasedriskofcomplicationsandmortalityfollowingrespiratorytractinfectionsinadultswithdownsyndrome AT marieclaudepotier immunedysregulationandtheincreasedriskofcomplicationsandmortalityfollowingrespiratorytractinfectionsinadultswithdownsyndrome AT alexandrabotte immunedysregulationandtheincreasedriskofcomplicationsandmortalityfollowingrespiratorytractinfectionsinadultswithdownsyndrome AT randallroper immunedysregulationandtheincreasedriskofcomplicationsandmortalityfollowingrespiratorytractinfectionsinadultswithdownsyndrome AT benjaminsredni immunedysregulationandtheincreasedriskofcomplicationsandmortalityfollowingrespiratorytractinfectionsinadultswithdownsyndrome AT jacquelinelondon immunedysregulationandtheincreasedriskofcomplicationsandmortalityfollowingrespiratorytractinfectionsinadultswithdownsyndrome AT williammobley immunedysregulationandtheincreasedriskofcomplicationsandmortalityfollowingrespiratorytractinfectionsinadultswithdownsyndrome AT andrestrydom immunedysregulationandtheincreasedriskofcomplicationsandmortalityfollowingrespiratorytractinfectionsinadultswithdownsyndrome AT andrestrydom immunedysregulationandtheincreasedriskofcomplicationsandmortalityfollowingrespiratorytractinfectionsinadultswithdownsyndrome AT eitanokun immunedysregulationandtheincreasedriskofcomplicationsandmortalityfollowingrespiratorytractinfectionsinadultswithdownsyndrome AT eitanokun immunedysregulationandtheincreasedriskofcomplicationsandmortalityfollowingrespiratorytractinfectionsinadultswithdownsyndrome AT eitanokun immunedysregulationandtheincreasedriskofcomplicationsandmortalityfollowingrespiratorytractinfectionsinadultswithdownsyndrome |
| _version_ |
1721360397160677376 |
| spelling |
doaj-cdbe71e884d1479b9d8fdfcd805105d12021-06-25T06:20:08ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-06-011210.3389/fimmu.2021.621440621440Immune Dysregulation and the Increased Risk of Complications and Mortality Following Respiratory Tract Infections in Adults With Down SyndromeTomer Illouz0Tomer Illouz1Arya Biragyn2Maria Florencia Iulita3Maria Florencia Iulita4Maria Florencia Iulita5Lisi Flores-Aguilar6Mara Dierssen7Mara Dierssen8Mara Dierssen9Ilario De Toma10Ilario De Toma11Ilario De Toma12Stylianos E. Antonarakis13Stylianos E. Antonarakis14Stylianos E. Antonarakis15Eugene Yu16Eugene Yu17Yann Herault18Marie-Claude Potier19Alexandra Botté20Randall Roper21Benjamin Sredni22Jacqueline London23William Mobley24Andre Strydom25Andre Strydom26Eitan Okun27Eitan Okun28Eitan Okun29The Leslie and Susan Gonda Multidisciplinary Brain Research Center, Bar-Ilan University, Ramat Gan, IsraelThe Paul Feder Laboratory on Alzheimer’s Disease Research, Bar-Ilan University, Ramat Gan, IsraelLaboratory of Molecular Biology and Immunology, National Institute on Aging, National Institute of Health, Baltimore, MD, United StatesSant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, SpainBiomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, SpainCenter of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, SpainDepartment of Anatomy and Cell Biology, McGill University, Montreal, QC, CanadaCenter for Genomic Regulation, The Barcelona Institute for Science and Technology, Barcelona, SpainUniversity Pompeu Fabra, Barcelona, Spain0Biomedical Research Networking Center for Rare Diseases (CIBERER), Barcelona, SpainCenter for Genomic Regulation, The Barcelona Institute for Science and Technology, Barcelona, SpainUniversity Pompeu Fabra, Barcelona, Spain0Biomedical Research Networking Center for Rare Diseases (CIBERER), Barcelona, Spain1Department of Genetic Medicine and Development, University of Geneva, Geneva, Switzerland2Medigenome, Swiss Institute of Genomic Medicine, Geneva, Switzerland3iGE3 Institute of Genetics and Genomics of Geneva, Geneva, Switzerland4The Children’s Guild Foundation Down Syndrome Research Program, Genetics and Genomics Program and Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States5Genetics, Genomics and Bioinformatics Program, State University of New York at Buffalo, Buffalo, NY, United States6Université de Strasbourg, CNRS, INSERM, Institut de Génétique Biologie Moléculaire et Cellulaire, IGBMC - UMR 7104 - Inserm U1258, Illkirch, France7Paris Brain Institute (ICM), CNRS UMR7225, INSERM U1127, Sorbonne Université, Hôpital de la Pitié-Salpêtrière, Paris, France7Paris Brain Institute (ICM), CNRS UMR7225, INSERM U1127, Sorbonne Université, Hôpital de la Pitié-Salpêtrière, Paris, France8Department of Biology, Indiana University-Purdue University Indianapolis, Indianapolis, IN, United States9The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, Israel0Université de Paris, BFA, UMR 8251, CNRS, Paris, France1Department of Neurosciences, University of California, San Diego, San Diego, CA, United States2Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry Psychology and Neuroscience, King’s College London, London, United Kingdom3South London and Maudsley NHS Foundation Trust, London, United KingdomThe Leslie and Susan Gonda Multidisciplinary Brain Research Center, Bar-Ilan University, Ramat Gan, IsraelThe Paul Feder Laboratory on Alzheimer’s Disease Research, Bar-Ilan University, Ramat Gan, Israel9The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, IsraelThe risk of severe outcomes following respiratory tract infections is significantly increased in individuals over 60 years, especially in those with chronic medical conditions, i.e., hypertension, diabetes, cardiovascular disease, dementia, chronic respiratory disease, and cancer. Down Syndrome (DS), the most prevalent intellectual disability, is caused by trisomy-21 in ~1:750 live births worldwide. Over the past few decades, a substantial body of evidence has accumulated, pointing at the occurrence of alterations, impairments, and subsequently dysfunction of the various components of the immune system in individuals with DS. This associates with increased vulnerability to respiratory tract infections in this population, such as the influenza virus, respiratory syncytial virus, SARS-CoV-2 (COVID-19), and bacterial pneumonias. To emphasize this link, here we comprehensively review the immunobiology of DS and its contribution to higher susceptibility to severe illness and mortality from respiratory tract infections.https://www.frontiersin.org/articles/10.3389/fimmu.2021.621440/fullDown syndromeimmune dysregulationhospitalizationrespiratory tract infectionsinterferonCOVID-19 |